| Literature DB >> 28683751 |
Kai-Yan Zhang1, Jin-Chun Xing2, Wei Li1, Zhun Wu1, Bin Chen1, Dong-Yu Bai3.
Abstract
BACKGROUND: Transurethral resection of bladder tumor (TURBT) is the standard approach to bladder tumors but suffers from several disadvantages. The aim of this study was to evaluate the safety and efficacy of a novel procedure of retrograde en bloc resection of bladder tumor (RERBT) with conventional monopolar resection electrode for the treatment of superficial bladder tumors.Entities:
Keywords: En-bloc resection; Non-muscle-invasive bladder cancer; Transurethral resection of bladder tumor
Mesh:
Year: 2017 PMID: 28683751 PMCID: PMC5501371 DOI: 10.1186/s12957-017-1192-6
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Clinicopathological characteristics of patients
| Variable | RERBT ( | C-TURBT ( |
| |
|---|---|---|---|---|
| Age (year) | 60.65 ± 13.08 | 60.80 ± 14.04 | 0.959 | |
| Size | 0.650 | |||
| ≤3 cm ( | 32 (80%) | 38 (76%) | ||
| >3 cm ( | 8 (20%) | 12 (24%) | ||
| Gender | 0.166 | |||
| Male | 35 (87.5%) | 38 (76%) | ||
| Female | 5 (12.5%) | 12 (24%) | ||
| Tumor multiplicity | 0.705 | |||
| Single | 29 (72.5%) | 38 (76%) | ||
| Multiple | 11 (27.5%) | 12 (24%) | ||
| Tumor morphology | 0.686 | |||
| Pedunculate | 28 (70%) | 33 (66%) | ||
| Flat | 12 (30%) | 17 (34%) | ||
| Stage | 0.119 | |||
| Ta | 15 (37.5%) | 27 (54%) | ||
| T1 | 25 (62.5%) | 23 (46%) | ||
| Grade (WHO2004) | 0.250 | |||
| LMP | 9 (22.5%) | 12 (24%) | ||
| LG | 22 (55%) | 23 (46%) | ||
| HG | 9 (22.5%) | 15 (30%) | ||
| Location | 0.753 | |||
| Lateral wall | 22 (55%) | 22 (44%) | ||
| Posterior wall | 5 (12.5%) | 8 (16%) | ||
| Anterior wall | 6 (15%) | 7 (14%) | ||
| Dome | 0 (0) | 3 (6%) | ||
| Trigone/bladder neck | 4 (10%) | 4 (8%) | ||
| Multiple | 3 (7.5%) | 6 (12%) | ||
RERBT retrograde en bloc resection of bladder tumor, C-TURBT conventional transurethral resection of bladder tumor, LMP papillary urothelial neoplasia of low malignant potential, LG low-grade papillary urothelial carcinoma, HG high-grade papillary urothelial carcinoma
Fig. 1a A 1.5-cm-diameter bladder tumor on the right bladder wall. b Macroscopic normal mucosa about 0.5 cm away from the tumor base was margined. Then, the bladder mucosa was subsequently cut in a “flash-firing” fashion. c After the deep muscle layer was reached when normal glistening yellow fat is seen between muscle layers, the loop was moved forward along the muscle layer. d The tumor was resected in one piece
Perioperative and follow-up data
| Variable | RERBT ( | C-TURBT ( |
|
|---|---|---|---|
| Operative time (min) | 36 ± 11.8 | 34 ± 13.6 | 0.464 |
| Complications | 0.7633 | ||
| Grade I | 1 (2.5%) | 2 (4%) | |
| Grade II | 6 (15%) | 8 (16%) | |
| Grade III | 0 | 0 | |
| Obturator nerve reflex | 9 (22%) | 12 (24%) | 0.867 |
| Bladder perforation | 2 (5%) | 4 (8%) | 0.689 |
| Presence of the detrusor muscle | |||
| Tumor specimen | (40/40) 100% | (27/50) 54% | 0.000 |
| Tumor base | (40/40) 100% | (35/50) 70% | 0.000 |
| Irrigation (day) | 1.16 ± 0.41 | 1.22 ± 0.45 | 0.518 |
| Catheterization (day) | 4.25 ± 2.04 | 4.65 ± 2.16 | 0.373 |
| Postoperative hospital stay (day) | 4.07 ± 0.57 | 4.18 ± 0.59 | 0.400 |
| Residual tumor on the base | 0 | 2 (5%) | 0.500 |
| Follow-up (months) | 10.8 ± 3.9 | 11.3 ± 4.22 | 0.775 |
| Cumulative recurrence | |||
| In field | 2 (5%) | 5 (10%) | 0.455 |
| Out of field | 6 (15%) | 7 (14%) | 0.893 |
| Over all | 8 (20%) | 12 (24%) | 0.650 |
| LMP | 0 | 0 | - |
| LG | 1 (2.5%) | 2 (4%) | 0.693 |
| HG | 7 (17.5%) | 10 (20%) | 0.763 |
RERBT retrograde en bloc resection of bladder tumor, C-TURBT conventional transurethral resection of bladder tumor, LMP papillary urothelial neoplasia of low malignant potential, LG low-grade papillary urothelial carcinoma, HG high-grade papillary urothelial carcinoma
Fig. 2Histologic findings of resected tumors. a The lamina propria mucosa was severely charred without muscular propria in a tumor in the C-TURBT group (×40). b The lamina propria mucosae remained intact, and the muscular propria was identified in a tumor in the RERBT group (×40)